News

The Company would like to clarify that the Notification Letter has no current effect on the listing or trading of the Company's securities on Nasdaq. Pursuant to Rule 5810 (c) (3) (A) of the Nasdaq ...
CHARLOTTE, N.C., June 10, 2025 (GLOBE NEWSWIRE) -- Magnera Corporation (NYSE: MAGN) today announced it will be added to the broad-market Russell 3000 ® Index following the annual reconstitution of the ...
Having previously identified a panel of candidate mRNA biomarkers with potential clinical relevance, Mainz Biomed will now begin the verification process in collaboration with Crown Bioscience, a ...
TAIPEI (Taiwan News) — The Ministry of National Defense tracked 16 Chinese military aircraft, eight naval vessels, and one official ship around Taiwan between 6 a.m. on Thursday and 6 a.m. on Friday.
Report Ocean has published a new report on the Saudi Arabia Telecom Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report offers a ...
Shareholders are invited to participate by live audio webcast at https://www.dorel.com/pages/shareholder-information Shareholders will have the ability to interact ...
Blade Air Mobility provides air transportation and logistics for hospitals across the United States, where it is one of the largest transporters of human organs for transplant, and for passengers, ...
Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the ...
At present, there is no ICI-based drug combination for the treatment of advanced MSS colorectal cancer, which is a cold tumor. Studies have shown that epigenetic regulators such as class I HDAC ...
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases ...
LOS ANGELES, CA, May 21, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), clinical-stage biopharmaceutical company developing cell therapies for AL ...
This open-label, multicenter, randomized controlled trial (RCT) was conducted in China to compare the efficacy and safety of satri-cel versus standard of care (SOC) in CLDN18.2 positive, advanced ...